179 related articles for article (PubMed ID: 37572261)
21. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
22. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
23. FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
Wright K
Oncology (Williston Park); 2020 Nov; 34(11):502-503. PubMed ID: 33206991
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation.
Dundar Y; Bagust A; Dickson R; Dodd S; Green J; Haycox A; Hill R; McLeod C; Walley T
Health Technol Assess; 2007 Jan; 11(1):1-90. PubMed ID: 17181984
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.
Hao X; Shen A; Wu B
Front Pharmacol; 2021; 12():573852. PubMed ID: 34290602
[No Abstract] [Full Text] [Related]
26. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Hu H; She L; Liao M; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Carbone DP; Huang J
Front Oncol; 2020; 10():1649. PubMed ID: 33014826
[No Abstract] [Full Text] [Related]
30. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Li Y; Liang X; Li H; Chen X
Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.
Liu S; Dou L; Wang K; Shi Z; Wang R; Zhu X; Song Z; Li S
Front Oncol; 2022; 12():899966. PubMed ID: 35936686
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab plus ipilimumab in malignant pleural mesothelioma.
Travert C; Tomasini P; Greillier L
Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722
[TBL] [Abstract][Full Text] [Related]
36. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
Shi Y; Pei R; Liu S
Front Oncol; 2022; 12():833773. PubMed ID: 36324594
[TBL] [Abstract][Full Text] [Related]
37. Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials.
Messori A; Trippoli S
J Chemother; 2023 Apr; 35(2):158-162. PubMed ID: 35411826
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
39. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer.
Yang SC; Kunst N; Gross CP; Wang JD; Su WC; Wang SY
Front Oncol; 2021; 11():760686. PubMed ID: 34956882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
